CAR-T免疫治疗在血液肿瘤治疗中的研究现状和挑战  

Current Status and Challenges of CAR-T Immunotherapy in Hematologic Malignancies——Review

作　　者：程新 王娅婕[2] 冯帅 吴亚运 杨同华[2] 赖洵[2] CHENG Xin1,2, WANG Ya-Jie2 ,FENG Shuai1,2, WU ga-Yun2, gANG Tong-Hua1,2, LAI Xun2(1 Medical College of Kunming University of Science and Technology, Kunming 650000, Yunnan Province, China ; 2 Department of Hemato- logy, The First People＇s Hospital Affiliated to Kunming University of Science and Technology,Kunming 650000, Yunnan Province, Chin)

机构地区：[1]昆明理工大学医学院,云南昆明650000 [2]昆明理工大学附属云南省第一人民医院血液科,云南昆明650000

出　　处：《中国实验血液学杂志》2018年第2期626-630,共5页Journal of Experimental Hematology

基　　金：国家自然科学基金(81460678);云南省科技计划项目(2012FB203);云南省卫生科技计划项目(2012WS0064)

摘　　要：嵌合抗原受体(chimeric antigen receptor,CAR)T细胞治疗技术经过近30年的发展,逐渐成为治疗血液肿瘤的新趋势。随着基因工程技术的不断发展,CAR-T技术已经经历了4代革新。CAR-T结构从单一信号分子发展到2个及2个以上共刺激分子,再到编码CAR基因或启动子,CAR-T技术发展不断成熟。CAR-T能特异识别肿瘤抗原,不受主要组织相容性复合体(major histocompatibility complex,MHC)限制性的影响,在治疗血液肿瘤领域取得了突破性的成果。本文就CAR-T的历史、结构和作用机理、以及在急性淋巴细胞白血病、急性髓系白血病、慢性髓系白血病、多发性骨髓瘤等血液肿瘤临床治疗中的研究现状和面临的挑战作一综述。The chimeric antigen receptor （CAR） T cell therapy has gradually became a new trend in the treatment of refractory and relapsed hematologic malignancies by developing for 30 years. With the exciting development of genetic engineering, CAR-T technology has subjected to 4 generations of innovation. Structure of CAR-T started from a single signal molecule to 2 or more than 2 co-stimulatory molecules, and then coding the CAR gene or promoter. CAR-T can specifically recognize tumor antigens, and does not be restricted by major histocompatihility complex （ MHC ）, thus making a breakthrough in clinical treatment. In this review, the history, structure and mechanism of action of CAR-T, as well as the cnrrcnt status and challenges of CAR-T immunotherapy in acute lymphoblastic leukemia, acute myeloid leukemia, chronic myeloid leukemia and multiple myeloma are summarized.

关 键 词：嵌合抗原受体 T细胞 血液肿瘤 免疫治疗 

分 类 号：R733[医药卫生—肿瘤] R930.51[医药卫生—临床医学]